Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.


Issue 20, 2018
Previous Article Next Article

Clinical analysis and quantitation of MB-102, a novel fluorescence tracer agent, in human plasma

Author affiliations

Abstract

A rapid analytical method for the quantitation of MB-102 (a fluorescent tracer agent) in human plasma using HPLC with fluorescence detection has been developed and validated. This new plasma sample preparation method, 1/100 direct dilution with phosphate buffered saline instead of typical protein precipitation, improves both robustness and assay efficiency by eliminating the need for sample drying and the need for an internal standard. The validation results show that the new method is robust, specific, precise, accurate, and has a wide linear dynamic range (0.4 ng mL−1 to 400 ng mL−1) with good recovery. The results from 59 clinical study subjects analyzed by both methods yield an excellent correlation with a slope of 1.015 and an R2 of 0.994. Sample preparation using direct dilution is easier and faster than the protein precipitation method, and is excellent for determining the MB-102 content in human plasma. The concentration of MB-102 in plasma as a function of time is used to calculate the glomerular filtration rate using a standard pharmacokinetic model.

Graphical abstract: Clinical analysis and quantitation of MB-102, a novel fluorescence tracer agent, in human plasma

Back to tab navigation

Supplementary files

Article information


Submitted
16 Mar 2018
Accepted
01 May 2018
First published
02 May 2018

Anal. Methods, 2018,10, 2376-2383
Article type
Paper

Clinical analysis and quantitation of MB-102, a novel fluorescence tracer agent, in human plasma

J. Shieh, I. Rochelle Riley and R. B. Dorshow, Anal. Methods, 2018, 10, 2376
DOI: 10.1039/C8AY00576A

Social activity

Search articles by author

Spotlight

Advertisements